Yestar Healthcare Eyes Oncology Diagnostics Lab JV in Singapore

MT Newswires Live
2025/10/20

Yestar Healthcare (HKG:2393) is considering forming a joint venture in Singapore with oncology platform New Genetron and potentially developing business in Indonesia, Malaysia, and Singapore, a Monday Hong Kong bourse filing said.

The JV, which intends to incorporate a new entity in Indonesia, will build and run clinical molecular diagnostics laboratories with a focus on precision oncology.

Another area of focus will be establishing local production facilities for IVD reagents and kits where appropriate, according to the healthcare consumables and equipment company.

The laboratories will offer early cancer screening, comprehensive genomic profiling, minimal residual disease monitoring, and non-invasive prenatal testing.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10